Not yet filed. No Q3 2026 Form 13F from RA Capital Management has been detected on SEC EDGAR yet. The deadline for the quarter ended Sep 30, 2026 is Monday, Nov 16, 2026.
From the fund's 2026 Q2 Form 13F (filed Aug 14, 2026) — the latest quarter fully processed on this site.
| Stock | Shares | Portfolio weight |
|---|---|---|
| ASND · Ascendis Pharma A/S | 10,281,496 | 23.83% |
| PBLS · PARABILIS MEDICINES INC | 28,933,371 | 6.88% |
| RYTM · RHYTHM PHARMACEUTICALS INC | 6,666,837 | 6.43% |
| PCVX · Vaxcyte, Inc. | 11,474,599 | 5.80% |
| SION · Sionna Therapeutics, Inc. | 9,905,045 | 3.79% |
| TYRA · TYRA BIOSCIENCES INC | 12,198,625 | 3.39% |
| EWTX · Edgewise Therapeutics, Inc. | 8,392,730 | 2.96% |
| NAMS · NewAmsterdam Pharma Co N.V. | 9,550,191 | 2.81% |
| COAG · HEMAB THERAPEUTICS HOLDINGS | 7,808,627 | 2.49% |
| SEPN · SEPTERNA INC | 6,995,858 | 2.04% |
Largest increase 2026 Q1 → 2026 Q2: ACRS (+87.0% of shares). New position in 2026 Q2: ASND (23.83% of the portfolio). Largest trim 2026 Q1 → 2026 Q2: HOWL (-64.3% of shares). Exited in 2026 Q2: DNTH, FULC, GRAL and 15 more.
Full record: RA Capital Management fund page · manager profile & 13F-clone record · Q3 2026 season tracker.
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.